Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study.

被引：12
|
作者：
Kasi, Pashtoon Murtaza [1 ]
Aushev, Vasily N. [2 ]
Ensor, Joe [2 ]
Langer, Nathan [3 ]
Wang, Christopher Gene [4 ]
Cannon, Timothy Lewis [5 ]
Berim, Lyudmyla Derby [6 ]
Feinstein, Trevor [7 ]
Grothey, Axel [8 ]
McCollom, Joseph William [9 ]
Kalmadi, Sujith R. [10 ]
Zakari, Ahmed [11 ]
Dayyani, Farshid [12 ]
Gravenor, Donald [13 ]
Meyer, Janelle Marie [14 ]
Sharif, Saima [15 ]
Jurdi, Adham A. [2 ]
Liu, Minetta C. [2 ]
Aleshin, Alexey [2 ]
Kopetz, Scott [16 ]
机构：
[1] NewYork Presbyterian Hosp, Englander Inst Precis Med, Weill Cornell Med, New York, NY USA
[2] Natera Inc, Austin, TX USA
[3] Virginia Canc Inst QCCA, Richmond, VA USA
[4] Alabama Oncol, Birmingham, AL USA
[5] Inova Schar Canc Inst, Fairfax, VA USA
[6] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[7] Piedmont Canc Inst, Atlanta, GA USA
[8] West Canc Ctr, Germantown, TN USA
[9] Parkview Canc Inst, Ft Wayne, IN USA
[10] Ironwood Canc & Res Ctr, Chandler, AZ USA
[11] Adventhlth Canc Inst, Orlando, FL USA
[12] Univ Calif Irvine, Dept Med, Div Hematol Oncol, Orange, CA USA
[13] Baptist Canc Ctr, Memphis, TN USA
[14] Oregon Oncol Specialists, Salem, OR USA
[15] Univ Iowa, Iowa City, IA USA
[16] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
283-237-255; 281-206-4760-6705; 261-376-454; 281-318-9508; 281-318-9493; 261-492-3532-2370-7650-2454; 261-376; 9; 7; 6; 4; 2;
D O I：
10.1200/JCO.2024.42.3_suppl.9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9 / 9
页数：1
相关论文
共 50 条
  • [31] Plasma central carbon metabolite changes associated with KRAS mutation and circulating tumor DNA (ctDNA) status in colorectal cancer (CRC).
    Kim, Daniel Myung
    Aguirre, Francesca Paola
    Gangi, Alexandra
    Alvarez, Rocio
    Zhou, Lisa
    ten Hoeve, Johanna
    Liao, Yi Jou
    Graeber, Thomas
    Hendifar, Andrew Eugene
    Osipov, Arsen
    Sankar, Kamya
    Cho, May Thet
    Abbas, Anser
    Davelaar, John
    Hitchins, Megan Philippa
    Gong, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 181 - 181
  • [32] Circulating tumor DNA (ctDNA) dynamics in patients with colorectal cancer (CRC) with molecular residual disease: Updated analysis from GALAXY study in the CIRCULATE-JAPAN.
    Yukami, Hiroki
    Nakamura, Yoshiaki
    Mishima, Saori
    Ando, Koji
    Bando, Hideaki
    Watanabe, Jun
    Hirata, Keiji
    Akazawa, Naoya
    Ikeda, Masataka
    Yokota, Mitsuru
    Kato, Kentaro
    Laliotis, George
    Aushev, Vasily N.
    Jurdi, Adham A.
    Liu, Minetta
    Kotani, Daisuke
    Oki, Eiji
    Takemasa, Ichiro
    Kato, Takeshi
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 6 - 6
  • [33] Preliminary analysis in Protector-C study: A prospective, multicenter cohort of utilizing circulating tumor DNA (ctDNA) methylation as postoperative surveillance for colorectal cancer (CRC)
    Liu, Z.
    Zhang, W.
    Chen, G.
    Wang, G.
    Chen, Y.
    Wang, Z.
    Liu, H.
    Yu, G.
    Zhang, Y.
    Dai, J.
    Yuan, Z.
    Hu, H.
    Zhou, L.
    Li, Y.
    Sun, P.
    Wu, Q.
    Jia, H.
    Wang, H.
    Liu, R.
    Wang, X.
    ANNALS OF ONCOLOGY, 2024, 35 : S462 - S462
  • [34] Circulating tumor DNA analysis informing adjuvant chemotherapy in locally advanced rectal cancer: The randomized AGITG DYNAMIC-Rectal study.
    Tie, Jeanne
    Cohen, Joshua D.
    Wang, Yuxuan
    Ginestet, Pablo Gonzalez
    Wong, Rachel
    Shapiro, Jeremy David
    Campbell, Rob
    Day, Fiona
    Hayes, Theresa M.
    Aghmesheh, Morteza
    Karapetis, Christos Stelios
    Popoli, Maria
    Dobbyn, Lisa
    Ptak, Janine
    Silliman, Natalie
    Douville, Christopher B.
    Papadopoulos, Nickolas
    Kinzler, Kenneth W.
    Vogelstein, Bert
    Gibbs, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 12 - 12
  • [35] Baseline characteristics as predictors of adjuvant chemotherapy (AC) discontinuations and modifications in stage III colorectal cancer (CRC) patients.
    Watanabe, Akie
    Yang, Charlie
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [36] Real-world adoption of 3 months of adjuvant oxaliplatin chemotherapy in patients with stage III colorectal cancer (CRC).
    Krishnan, Tharani
    Vasconcelos, Joao Paulo Solar
    Lim, Howard J.
    Loree, Jonathan M.
    Davies, Janine Marie
    Gill, Karamjit
    Gill, Sharlene
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 83 - 83
  • [37] ECOG performance status as a predictor of adjuvant chemotherapy (AC) toxicities in stage III colorectal cancer (CRC) patients.
    Watanabe, Akie
    Yang, Charlie
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [38] Clinical implementation of the universal tumor screening with the mismatch repair (MMR) proteins on decision impact of adjuvant chemotherapy in patients with resected stage II/III colorectal cancer (CRC)
    Yamamoto, Y.
    Tsukada, Y.
    Bando, H.
    Sasaki, T.
    Nishizawa, Y.
    Kojima, M.
    Kuwata, T.
    Ito, M.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [39] Prognostic impact of comorbidity in stage II-III colorectal cancer (CRC) patients treated with surgery and neoadjuvant/adjuvant chemotherapy: a single Institution observational study
    Baretti, M.
    Giordano, L.
    Rimassa, L.
    Tronconi, M. C.
    Pressiani, T.
    Bozzarelli, S.
    Personeni, N.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [40] Combined genomic and epigenomic assessment of cell-free circulating tumor DNA (ctDNA) improves assay sensitivity in early-stage colorectal cancer (CRC)
    Kim, Seung-Tae
    Raymond, Victoria M.
    Park, Joon Oh
    Zotenko, Elena
    Park, Young Suk
    Schultz, Matthew
    Kang, Won Ki
    Westesson, Oscar
    Kim, Hee-Cheol
    He, Yupeng
    Odegaard, Justin I.
    Mortimer, Stefanie A.
    Greenleaf, William J.
    Jaimovich, Ariel
    Lee, Jeeyun
    Talasaz, AmirAli
    CANCER RESEARCH, 2019, 79 (13)
12345